NCT06855069

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 468 (estimated)
• Sponsor: Hansoh BioMedical R&D Company · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	HS-20089	HS-20089 dose 1
DRUG	Paclitaxel	Paclitaxel dose 2
DRUG	Doxorubicin	Doxorubicin dose 3
DRUG	Topotecan	Topotecan dose 4

Timeline

• Start date: 2025-03-13
• Primary completion: 2027-03-07
• Completion: 2029-03-07
• First posted: 2025-03-03
• Last updated: 2025-12-17

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study